UB-625b

UB-625b is a neutralizing monoclonal antibody developed by United Biopharma (UBP Asset) for the treatment and prevention of COVID-19. It is designed to target the spike protein of the SARS-CoV-2 virus, specifically blocking its interaction with the human Angiotensin-Converting Enzyme 2 (ACE2) receptor to prevent viral entry into host cells. UB-625b is typically developed as part of a dual-antibody combination therapy alongside UB-625a. Preclinical and early clinical evaluations have demonstrated that this combination maintains neutralizing activity against various SARS-CoV-2 variants, including the Alpha (UK), Beta (South Africa), Gamma (Brazil), and Delta (India) strains.